CO2021013699A2 - Líneas celulares productoras diseñadas genéticamente y métodos de elaboración y uso de las mismas - Google Patents

Líneas celulares productoras diseñadas genéticamente y métodos de elaboración y uso de las mismas

Info

Publication number
CO2021013699A2
CO2021013699A2 CONC2021/0013699A CO2021013699A CO2021013699A2 CO 2021013699 A2 CO2021013699 A2 CO 2021013699A2 CO 2021013699 A CO2021013699 A CO 2021013699A CO 2021013699 A2 CO2021013699 A2 CO 2021013699A2
Authority
CO
Colombia
Prior art keywords
cell lines
genetically engineered
methods
making
producer cell
Prior art date
Application number
CONC2021/0013699A
Other languages
English (en)
Spanish (es)
Inventor
Aubrey R Tiernan
Nicholas Richards
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Publication of CO2021013699A2 publication Critical patent/CO2021013699A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CONC2021/0013699A 2019-04-12 2021-10-14 Líneas celulares productoras diseñadas genéticamente y métodos de elaboración y uso de las mismas CO2021013699A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962833548P 2019-04-12 2019-04-12
US201962839207P 2019-04-26 2019-04-26
US202062979483P 2020-02-21 2020-02-21
PCT/US2020/027489 WO2020210507A1 (en) 2019-04-12 2020-04-09 Engineered producer cell lines and methods of making and using the same

Publications (1)

Publication Number Publication Date
CO2021013699A2 true CO2021013699A2 (es) 2021-10-29

Family

ID=70465550

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0013699A CO2021013699A2 (es) 2019-04-12 2021-10-14 Líneas celulares productoras diseñadas genéticamente y métodos de elaboración y uso de las mismas

Country Status (15)

Country Link
US (2) US12018288B2 (cg-RX-API-DMAC7.html)
EP (2) EP3953458A1 (cg-RX-API-DMAC7.html)
JP (2) JP7560475B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210152514A (cg-RX-API-DMAC7.html)
CN (1) CN113966395B (cg-RX-API-DMAC7.html)
AU (1) AU2020270960B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020391A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136246A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021013699A2 (cg-RX-API-DMAC7.html)
IL (1) IL287106A (cg-RX-API-DMAC7.html)
MX (1) MX2021012489A (cg-RX-API-DMAC7.html)
PH (1) PH12021552577A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202110904PA (cg-RX-API-DMAC7.html)
TW (1) TWI859216B (cg-RX-API-DMAC7.html)
WO (1) WO2020210507A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12054738B2 (en) 2020-07-30 2024-08-06 Shape Therapeutics Inc. Stable cell lines for inducible production of rAAV virions
JP2024531138A (ja) 2021-08-11 2024-08-29 ウルトラジェニックス ファーマシューティカル インコーポレイテッド 筋ジストロフィーを処置するための組成物および方法
JP2024537896A (ja) 2021-10-18 2024-10-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞
AR127674A1 (es) 2021-10-18 2024-02-21 Regeneron Pharma Células de mamífero que comprenden genes cas9 integrados para producir sitios de integración estables, y células de mamífero que comprenden sitios de integración estables y otros sitios
WO2023077078A1 (en) 2021-10-29 2023-05-04 Ultragenyx Pharmaceutical Inc. Engineered cell lines for increased production of recombinant adeno-associated virus (raav)
CA3245327A1 (en) 2022-03-07 2023-09-14 Ultragenyx Pharmaceutical Inc. MODIFIED BATCH-BASED AAV PRODUCTION SYSTEMS AND PROCESSES
CN122161940A (zh) * 2023-10-12 2026-06-05 塞维克制药有限责任公司 影响重组aav生产的细胞因子
WO2025226558A1 (en) 2024-04-22 2025-10-30 Ultragenyx Pharmaceutical Inc. Multi-step filtration and clarification methods for recombinant adeno-associated virus purification
WO2026078664A1 (en) 2024-10-10 2026-04-16 Instituto De Biologia Experimental E Tecnológica (Ibet) Transcription factor enhancing recombinant adeno-associated virus production, products, methods and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5387484A (en) 1992-07-07 1995-02-07 International Business Machines Corporation Two-sided mask for patterning of materials with electromagnetic radiation
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
WO1996017947A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US5688676A (en) 1995-06-07 1997-11-18 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
CA2270285A1 (en) 1996-12-18 1998-06-25 Targeted Genetics Corporation Aav split-packaging genes and cell lines comprising such genes for use in the production of recombinant aav vectors
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
CA2995542A1 (en) * 1997-09-05 1999-03-11 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
WO2000024916A1 (en) 1998-10-27 2000-05-04 Crucell Holland B.V. Improved aav vector production
DE19905501B4 (de) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
US7510872B2 (en) 2003-02-26 2009-03-31 Nationwide Children's Hospital Recombinant adeno-associated virus production
ATE530667T1 (de) 2005-05-27 2011-11-15 Evotec Neurosciences Gmbh Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit
PT3272872T (pt) 2005-10-20 2020-06-26 Uniqure Ip Bv Vetores aav melhorados produzidos em células de insetos
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
BR112015018493A2 (pt) 2013-02-05 2017-08-22 Univ Georgia Linhagens celulares para produção de vírus e métodos de uso
CN104592364B (zh) * 2013-10-30 2018-05-01 北京大学 定点突变和定点修饰的腺相关病毒、其制备方法及应用
GB201401707D0 (en) 2014-01-31 2014-03-19 Sec Dep For Health The Adeno-associated viral vectors
US20160319277A1 (en) 2015-01-28 2016-11-03 The Johns Hopkins University METHODS OF IMPROVED PROTEIN PRODUCTION USING MIRNAs AND SIRNAs
ES2938833T3 (es) 2016-03-28 2023-04-17 Ultragenyx Pharmaceutical Inc Métodos de inactivación térmica de adenovirus
EP3484493A4 (en) 2016-07-12 2019-12-25 Ultragenyx Pharmaceutical Inc. USE OF GLUCOCORTICOID ANALOGS TO INCREASE THE PERFORMANCE OF RECOMBINANT ADENO-ASSOCIATED VIRUSES
ES3012649T3 (en) 2016-10-14 2025-04-09 Ultragenyx Pharmaceutical Inc Use of tonicifying agents to enhance recombinant adeno-associated virus yield
US20200048641A1 (en) 2017-03-22 2020-02-13 Ultragenyx Pharmaceutical Inc. Methods for enhancing yield of recombinant adeno-associated virus
EP3601581B1 (en) 2017-03-22 2025-04-30 Ultragenyx Pharmaceutical Inc. CELL CULTURE METHODS INVOLVING HDAC INHIBITORS OR REP PROTEINS
EP3621734A4 (en) 2017-05-09 2020-12-30 Ultragenyx Pharmaceutical Inc. MODULAR PROCESS FOR THE PRODUCTION OF TRANSFECTION REAGENTS
CA3088538A1 (en) 2018-01-19 2019-07-25 The University Of North Carolina At Chapel Hill Methods and compositions for inhibition of innate immune response associated with aav transduction
US12577539B2 (en) 2019-04-26 2026-03-17 The Regents Of The University Of California Cells for enhanced production of adeno-associated virus
WO2023077078A1 (en) * 2021-10-29 2023-05-04 Ultragenyx Pharmaceutical Inc. Engineered cell lines for increased production of recombinant adeno-associated virus (raav)

Also Published As

Publication number Publication date
MX2021012489A (es) 2021-11-12
US12018288B2 (en) 2024-06-25
WO2020210507A1 (en) 2020-10-15
EP3953458A1 (en) 2022-02-16
BR112021020391A2 (pt) 2022-02-08
AU2020270960A1 (en) 2021-11-04
SG11202110904PA (en) 2021-10-28
JP2022526646A (ja) 2022-05-25
EP4603579A3 (en) 2025-12-10
TW202104593A (zh) 2021-02-01
CA3136246A1 (en) 2020-10-15
PH12021552577A1 (en) 2022-04-04
US20200325455A1 (en) 2020-10-15
CN113966395A (zh) 2022-01-21
US20240376440A1 (en) 2024-11-14
IL287106A (en) 2021-12-01
TWI859216B (zh) 2024-10-21
JP2024107295A (ja) 2024-08-08
AU2020270960B2 (en) 2026-01-29
KR20210152514A (ko) 2021-12-15
EP4603579A2 (en) 2025-08-20
CN113966395B (zh) 2025-07-04
JP7706607B2 (ja) 2025-07-11
JP7560475B2 (ja) 2024-10-02

Similar Documents

Publication Publication Date Title
BR112021021725A2 (pt) Proteínas policlonais recombinantes e métodos de uso das mesmas
PH12021552577A1 (en) Engineered producer cell lines and methods of making and using the same
CO2021006362A2 (es) Construcciones de ácido nucleico y métodos de uso
MX2019006438A (es) Produccion de celulas modificadas para terapia de celulas adoptivas.
CL2018000740A1 (es) Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden
BR112021016984A2 (pt) Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação
AR118560A2 (es) Métodos y composiciones que comprenden polipéptidos recombinantes purificados
AR120858A1 (es) VARIANTES DE a-GLUCOSIDASA ÁCIDA MANIPULADAS POR INGENIERÍA
MX2018005274A (es) Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t.
MX2022001977A (es) Poblaciones de celulas t gamma delta t ex vivo.
BR112022005963A2 (pt) Células com expressão de transgenes sustentada
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
MX2018003144A (es) Dominios de superfamilia de inmunoglobulina de variante ajustable y terapia con células genéticamente modificadas.
MX2016014813A (es) Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos.
PE20211660A1 (es) Neoantigenos prostaticos y sus usos
BR112022009290A2 (pt) Terapia para malignidades de células hematopoiéticas com o uso de células t geneticamente modificadas visando cd70
CL2016002142A1 (es) Proteínas de fusión tatk-cdkl5, composiciones, formulaciones y uso de estas
AR117950A1 (es) Receptores quiméricos de steap1 y composición farmacéutica que los contienen
CO2020013699A2 (es) Composiciones aav, métodos de fabricación y métodos de uso
CO2021013970A2 (es) Células t específicas del antígeno del virus multi-respiratorio y métodos para fabricar y usar el mismo terapéuticamente
CL2021003295A1 (es) Composiciones de virus adenoasociados para la transferencia del gen de arsa y métodos de uso de las mismas.
MX2020004063A (es) Sistemas y metodos para producir celulas b modificadas geneticamente para expresar anticuerpos seleccionados.
PE20190966A1 (es) Factor viii direccionado a los globulos rojos y metodo para su uso
MX374756B (es) Organizacion de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos.
BR112023018832A2 (pt) Composições de proteínas de fusão quiméricas modificadas e métodos de uso das mesmas